The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% for placebo (p- Statistically significant ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product ...

Notably, the study also showed that treatment with pimicotinib provided statistically significant and clinically meaningful improvements in secondary endpoints associated with important patient ...

The primary objective of this Phase 1 randomized, double-blind, placebo-controlled, multi-part single and multiple ascending dose clinical study is to evaluate the safety, tolerability and ...

Monthly 140 mg erenumab injections are a safe and effective treatment for patients with nonopioid chronic migraine and medication overuse headaches.

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

The incidence of adverse events was similar among study groups (placebo = 84.6%, levetiracetam 2000 mg/day = 83.3%, levetiracetam 4000 mg/day = 84.2%) in the double-blind treatment period.

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update Phase 2 Long COVID Results Expected Soon Dogwood Therapeutics, Inc.

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Q3 2024 Earnings Call Transcript November 7, 2024 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.34, expectations were $-1.37. Operator: Good morning and welcome to ...

An international group of researchers, led by the Smith Bee Lab at Auburn University, have now shown that honey bees ...

What does the Netflix show "Love Is Blind, Habibi" reveal about the psychology of attraction, and can love grow without ...